background image

Ten reasons the FTSE 100 could hit 10,000 this year

Equities 3 minutes to read
Note: This is marketing material. This article is not investment advice, capital is at risk.

Ten reasons the FTSE 100 gets to 10,000 by Christmas

 

Best of times, worst of times: The FTSE was a safe harbour in a stormy market earlier this year and since everything has started grinding up the UK blue chips have not missed out. The FTSE 100 hit a fresh intraday record high today, led by miners and financials.  So, there are dynamics at play here that make the FTSE attractive for a variety of reasons, which may explain why it could reach 10k this year. 
  1. Diversification: Some modest ongoing diversification away from US leadership, particularly a heavy overweight tech position, has been a factor behind the FTSE’s ascent this year and can continue as US economic policy uncertainty remains elevated and investors seek some relative shelter from their USD exposure that is implicit with buying US stocks.
  2. Valuation: Sky high valuations in the US don’t lead to a bear market – recessions do. So it’s too easy to say that the UK is attractive from a valuation perspective. But this has been a strong argument for a while and is starting to be evidenced as the key bull thesis for UK stocks. (it has been before, but crucially the macro environment has changed). The FTSE 100 trades about 14.3x earnings – to get to 10,000 only requires a modest uplift to 15x. Meanwhile the S&P 500 trades about 22.6x earnings. Relative valuations have started to matter again due to macroeconomic conditions and higher terminal rates. The old TINATA - there is no alternative to America – trade is no longer quite as easy as it once was. 
  3. Yield: The FTSE’s dividend yield is also the highest in developed markets. Investors may be tempted increasingly towards dividend strategies going forward. 
  4. Composition: Index makeup matters - defensives, longer-term plays, companies that are not being disrupted by tech (eg miners and defence, drinks, tobacco). Old fashioned stuff like free cash flow and balance sheets have mattered once more. 
  5. The majority of the FTSE’s earnings are from cyclical and value sectors – a positive when inflationary environment. All the things that held the UK index back in the 2010s are reversing into the more bullish ‘Roaring 20s’. The decade of low growth and low rates/inflation has been replaced by a far more dynamic, higher rate, higher inflation, higher nominal growth environment. 
  6. UK weakness. Ok hear me out. The absolute chaos in the UK fiscal position could be a positive for the FTSE 100 because gilts and sterling are set to come under pressure, which will make the index look better and more appealing. The interesting thing is that we’ve nearly hit 9,500 as sterling has seen a big rally against the dollar this year – magnifying the relative performance vs the US. 
  7. Bonfire of the Vanities: November 5th could see further uncertainty as the Supreme Court, which begins its new term on Monday, considers whether tariffs are legal. This Bonfire of the Vanities could be important for how the world sees US exceptionalism against Trump’s economic policymaking. Does this see Trump unravel like Sherman McCoy? My bet is the Supreme Court backs Trump and he has even more power to impose his will on the economy and markets. 
  8. On a macro-to-micro level, I still want to look at the 4D trade – debt debasement & dollar devaluation is a factor favouring the FTSE, I think, due to the composition of basic resources stocks – i.e. miners. There is likely more in the gold trade long-term, even if we see near-term pullbacks and consolidation just shy of the $4k/oz level. Energy transition, AI and other megatrends should support miners. 
  9. Defence: There is little sign that investor appetite for defence stocks is waning after a big rally this year. Russian pressure on Nato continues and the paradigm shift in defence spending across Europe remains a tailwind, particularly as we start to see where the defence pounds end up. 
  10. Pharma: the recent jump in AstraZeneca and others following Pfizer’s deal with the US administration is a sign that the worst of the tariff-related uncertainty may be over. This can be a good tailwind for the index. 

 

 

 

This content is marketing material. 

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Market Ltd. (SCML) provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice or a recommendation.

SCML content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

SCML partners with companies that provide compensation for promotional activities conducted on its platform. Some partners also pay retrocessions contingent on clients investing in products from those partners. 

While SCML receives compensation from these partnerships, all educational and research content remains focused on providing information to clients.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. SCML does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer and notification on non-independent investment research for more details.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is part of the J. Safra Sarasin Group.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992